Literature DB >> 17318668

Functional and anatomical magnetic resonance imaging in Parkinson's disease.

Alain Dagher1, Atsuko Nagano-Saito.   

Abstract

For the past 15 years, measurements of cerebral blood flow as an indicator of neuronal activity have been used to gain a better understanding of the neural basis of motor and cognitive deficits in Parkinson's disease. The initial studies, using positron emission tomography, yielded results in keeping with the hypothesis that symptoms result from excessive cortical inhibition from cortico-striatal loops. However, subsequent studies with functional magnetic resonance imaging (fMRI) have shown that specific aspects of the paradigms used, such as the need to pay attention to one's movements, have a significant impact on activation patterns, which may complicate the interpretation of results. Functional neuroimaging has also been used to investigate the causes of cognitive impairment in Parkinson's disease. While some studies implicate dopamine loss in striatum, more recent investigations using anatomical MRI to measure cortical atrophy suggest that some cognitive deficits are attributable to direct cortical involvement by the disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17318668     DOI: 10.1007/s11307-007-0089-0

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.484


  78 in total

1.  A general statistical analysis for fMRI data.

Authors:  K J Worsley; C H Liao; J Aston; V Petre; G H Duncan; F Morales; A C Evans
Journal:  Neuroimage       Date:  2002-01       Impact factor: 6.556

2.  The role of the striatum and hippocampus in planning: a PET activation study in Parkinson's disease.

Authors:  A Dagher; A M Owen; H Boecker; D J Brooks
Journal:  Brain       Date:  2001-05       Impact factor: 13.501

3.  Motor imagery in normal subjects and Parkinson's disease patients: an H215O PET study.

Authors:  M Samuel; A O Ceballos-Baumann; H Boecker; D J Brooks
Journal:  Neuroreport       Date:  2001-03-26       Impact factor: 1.837

Review 4.  On the nature of the BOLD fMRI contrast mechanism.

Authors:  Nikos K Logothetis; Josef Pfeuffer
Journal:  Magn Reson Imaging       Date:  2004-12       Impact factor: 2.546

Review 5.  The functional organization of working memory processes within human lateral frontal cortex: the contribution of functional neuroimaging.

Authors:  A M Owen
Journal:  Eur J Neurosci       Date:  1997-07       Impact factor: 3.386

Review 6.  The functional anatomy of basal ganglia disorders.

Authors:  R L Albin; A B Young; J B Penney
Journal:  Trends Neurosci       Date:  1989-10       Impact factor: 13.837

7.  Grammatical and resource components of sentence processing in Parkinson's disease: an fMRI study.

Authors:  M Grossman; A Cooke; C DeVita; C Lee; D Alsop; J Detre; J Gee; W Chen; M B Stern; H I Hurtig
Journal:  Neurology       Date:  2003-03-11       Impact factor: 9.910

Review 8.  Physiology of basal ganglia disorders: an overview.

Authors:  M Hallett
Journal:  Can J Neurol Sci       Date:  1993-08       Impact factor: 2.104

9.  Supplementary and primary sensory motor area activity in Parkinson's disease. Regional cerebral blood flow changes during finger movements and effects of apomorphine.

Authors:  O Rascol; U Sabatini; F Chollet; P Celsis; J L Montastruc; J P Marc-Vergnes; A Rascol
Journal:  Arch Neurol       Date:  1992-02

10.  Fronto-striatal cognitive deficits at different stages of Parkinson's disease.

Authors:  A M Owen; M James; P N Leigh; B A Summers; C D Marsden; N P Quinn; K W Lange; T W Robbins
Journal:  Brain       Date:  1992-12       Impact factor: 13.501

View more
  8 in total

1.  Impairment of executive performance after transcranial magnetic modulation of the left dorsal frontal-striatal circuit.

Authors:  Odile A van den Heuvel; Helene C Van Gorsel; Dick J Veltman; Ysbrand D Van Der Werf
Journal:  Hum Brain Mapp       Date:  2011-11-11       Impact factor: 5.038

2.  Pharmacological MRI (phMRI) monitoring of treatment in hemiparkinsonian rhesus monkeys.

Authors:  Liming Luan; Feng Ding; Yi Ai; Anders Andersen; Peter Hardy; Eric Forman; Greg A Gerhardt; Don M Gash; Richard Grondin; Zhiming Zhang
Journal:  Cell Transplant       Date:  2008       Impact factor: 4.064

3.  Hypoactivation of the primary sensorimotor cortex in de novo Parkinson's disease : a motor fMRI study under controlled conditions.

Authors:  Carlo Tessa; Claudio Lucetti; Stefano Diciotti; Lorenzo Paoli; Paolo Cecchi; Marco Giannelli; Filippo Baldacci; Andrea Ginestroni; Claudio Vignali; Mario Mascalchi; Ubaldo Bonuccelli
Journal:  Neuroradiology       Date:  2011-09-17       Impact factor: 2.804

Review 4.  The centre of the brain: topographical model of motor, cognitive, affective, and somatosensory functions of the basal ganglia.

Authors:  Marie Arsalidou; Emma G Duerden; Margot J Taylor
Journal:  Hum Brain Mapp       Date:  2012-06-19       Impact factor: 5.038

5.  Psychometrically matched tasks evaluating differential fMRI activation during form and motion processing.

Authors:  Andrea N Snyder; Marcie A Bockbrader; Angela M Hoffa; Mario A Dzemidzic; Thomas M Talavage; Donald Wong; Mark J Lowe; Brian F O'Donnell; Anantha Shekhar
Journal:  Neuropsychology       Date:  2011-09       Impact factor: 3.295

6.  Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia.

Authors:  Sylvia Navailles; Philippe De Deurwaerdère
Journal:  Parkinsons Dis       Date:  2011-10-11

7.  Accounting for movement increases sensitivity in detecting brain activity in Parkinson's disease.

Authors:  Štefan Holiga; Harald E Möller; Tomáš Sieger; Matthias L Schroeter; Robert Jech; Karsten Mueller
Journal:  PLoS One       Date:  2012-05-01       Impact factor: 3.240

8.  Functional reorganization of motor and limbic circuits after exercise training in a rat model of bilateral parkinsonism.

Authors:  Zhuo Wang; Kalisa G Myers; Yumei Guo; Marco A Ocampo; Raina D Pang; Michael W Jakowec; Daniel P Holschneider
Journal:  PLoS One       Date:  2013-11-21       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.